Back to Journals » International Journal of Nanomedicine » Volume 4

Water-soluble fullerene (C60) inhibits the osteoclast differentiation and bone destruction in arthritis

Authors Yudoh K , Karasawa R, Masuko K, Kato T

Published 20 October 2009 Volume 2009:4 Pages 233—239


Review by Single anonymous peer review

Peer reviewer comments 3

Kazuo Yudoh1, Rie Karasawa1, Kayo Masuko2, Tomohiro Kato2

1Department of Frontier Medicine, 2Department of Biochemistry, Institute of Medical Science, St. Marianna University School of Medicine, Kawasaki, Japan

Abstract: Recently, it has been demonstrated that oxygen free radicals have an important role as a signaling messenger in the receptor activator NFκB (RANK) signal pathway required for osteoclast differentiation. The aim of this study was to examine the potential of a strong free-radical scavenger, water-soluble fullerene (C60), as a protective agent against the RANK-induced osteoclastogenesis and osteoclastic bone destruction in arthritis, both in vitro and in vivo. The effects of C60 on the RANK-induced osteoclastogenesis and osteoclastic bone resorption were examined in vitro. Adjuvant-induced arthritic rats were used as an animal model of arthritis. Rats were divided into two subgroups: control and treatment with C60 at 1.0 µM. The left ankle joint was injected intra-articularly with water-soluble C60 (20 µl) in the C60-treated group, while, as a control, the left ankle joint in the control rats received phosphate-buffered saline (20 µl) once weekly for eight weeks. Ankle joint tissues were prepared for histologic analysis. C60 significantly inhibited the responses of osteoclast precursor cells to RANK ligand, including osteoclast differentiation and osteoclastic bone resorption in vitro. In adjuvant-induced arthritic rats, intra-articular treatment with C60 in vivo reduced the number of osteoclasts and alleviated bone resorption and destruction in the joints, while control ankle joints showed progression of joint destruction with time. These findings indicate that C60 downregulates the RANK-induced osteoclast differentiation and is a potential therapeutic agent for inhibition of osteoclastic bone destruction in arthritis.

Keywords: fullerene, osteoclast, bone resorption arthritis, antioxidant

Creative Commons License © 2009 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.